Abstract The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA)
Consortium is a collaborative network of researchers working together on a range of large 

Introduction Genetic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have
been crucial in advancing the understanding of Alzheimer's disease (AD) pathophysiology 

After drifting apart for 100 years, the two worlds of genetics—quantitative genetics and
molecular genetics—are finally coming together in genome-wide association (GWA) 

The role of the Alzheimer's Disease Neuroimaging Initiative Genetics Core is to facilitate the
investigation of genetic influences on disease onset and trajectory as reflected in structural 

Brain imaging genomics is an emerging data science field, where integrated analysis of
brain imaging and genomics data, often combined with other biomarker, clinical, and 

A genome-wide, whole brain approach to investigate genetic effects on neuroimaging
phenotypes for identifying quantitative trait loci is described. The Alzheimer's Disease 

Background With the exception of APOE 4 allele, the common genetic risk factors for
sporadic Alzheimer's Disease (AD) are unknown. Methods and Findings We completed a 

In this review, we discuss recent work by the ENIGMA Consortium (http://enigma. ini. usc.
edu)–a global alliance of over 500 scientists spread across 200 institutions in 35 countries 

Deposition of amyloid- (A) in the cerebral cortex is thought to be a pivotal event in
Alzheimer's disease (AD) pathogenesis with a significant genetic contribution. Molecular 

Objectives: CSF levels of A1-42, t-tau, and p-tau181p are potential early diagnostic
markers for probable Alzheimer disease (AD). The influence of genetic variation on these